IRCT20120524009844N8已完成3 期
Therapeutic Effects of Adalimumab in Patients with Resistant Psoriasis Patients by DLQ and PASI Questionnaires
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Confirmed pseuriasis
- •Patients without responce to previous treatments
- •Don’t use of other drugs and herbal supplments
- •Resistance to atleast one systemic treatment
排除标准
- •Allergy to Adalimumab
- •Having active inflammation such as tuberculosis, malignancies and etc
- •Neurological disorders
- •Hematological disorders
- •Moderate to severe heart failure
- •Pregnant and breast feeding woman
- •Mental retared patients
研究者
相似试验
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-BEAbbott GmbH & Co. KG500
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-SEAbbott GmbH & Co. KG500
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-DEAbbott GmbH & Co. KG500
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-DKAbbott GmbH & Co. KG500
进行中（未招募）
不适用
Safety and Efficacy of Adalimumab in Patients with Psoriatic Arthritis (PsA)- An Open-Label, Multinational Study to Evaluate the Response to Every-Other Week Adalimumab When Added to Insufficient Standard Therapy Including Patients who Failed Prior Treatment With Other TNF-Inhibitors (STEREO) - STEREOPsoriatic ArthritisEUCTR2005-001185-14-FIAbbott GmbH & Co. KG500